Dec 9, 2025 09:16AM
Nov 12, 2024 04:00PM
Aug 19, 2024 08:59AM
Aug 6, 2024 04:00PM
Jul 31, 2024 10:15AM
Jul 31, 2024 09:00AM
Jul 31, 2024 09:00AM GeoVax Announces Phase 2 Plans for Gedeptin® Cancer Therapy Following Clinical Advisory Committee Review
Jul 9, 2024 09:10AM
Jul 9, 2024 09:09AM
Jun 20, 2024 10:00AM
Jun 18, 2024 07:10AM
Jun 18, 2024 07:09AM
Feb 13, 2024 09:00AM
Feb 13, 2024 09:00AM GeoVax Announces Multiple Patent Issuances and Allowances
Jan 4, 2024 09:00AM
Nov 8, 2023 04:00PM
Oct 24, 2023 09:01AM
Oct 24, 2023 09:00AM
Oct 9, 2023 09:00AM
Sep 26, 2023 09:01AM
Sep 26, 2023 09:00AM GeoVax Secures Multi-Product License for ProBioGen's AGE1.CR.pIX® Suspension Cell Line to Bolster MVA-Based Vaccine Development
Sep 26, 2023 09:00AM
Sep 12, 2023 09:00AM
Sep 11, 2023 09:00AM
Aug 9, 2023 04:00PM
Jul 10, 2023 09:00AM
Jun 28, 2023 09:00AM
May 4, 2023 04:00PM GeoVax Reports 2023 First Quarter Financial Results and Provides Corporate Update
Mar 23, 2023 04:00PM
Feb 15, 2023 09:01AM
Feb 15, 2023 09:00AM
Feb 7, 2023 09:05AM
Feb 7, 2023 09:00AM
Nov 9, 2022 04:00PM
Oct 11, 2022 09:00AM GeoVax to Present at Vaccines Summit-2022
Oct 6, 2022 09:00AM
Sep 7, 2022 09:00AM
Sep 1, 2022 09:00AM
Aug 3, 2022 04:00PM
Jul 28, 2022 09:02AM
Jul 28, 2022 09:00AM
Jul 26, 2022 09:00AM GeoVax to Report Second Quarter 2022 Financial Results on Wednesday, August 3, 2022 and Provide Corporate Update
Jun 13, 2022 09:00AM
Jun 7, 2022 09:00AM
May 25, 2022 01:48PM
May 25, 2022 01:47PM
May 24, 2022 09:01AM
May 24, 2022 09:00AM
May 4, 2022 09:00AM GeoVax Announces Upcoming Presentations at Scientific Conferences
Apr 27, 2022 04:00PM

312,667 total articles have been posted to this entity.

Click Here to Sign-Up for StreetInsider.com Premium to View All